| 0 (0%) | 04-24 22:05 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 42.07  |
1-year : | 49.14 |
| Resists | First : | 36.02 |
Second : | 42.07 |
| Pivot price | 34.58 |
|||
| Supports | First : | 34.15 |
Second : | 33 |
| MAs | MA(5) : | 35.23 |
MA(20) : | 34.64 |
| MA(100) : | 34.42 |
MA(250) : | 35.87  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 89.7 |
D(3) : | 81 |
| RSI | RSI(14): 62.9 |
|||
| 52-week | High : | 44.83 | Low : | 30.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AVA ] has closed below upper band by 11.4%. Bollinger Bands are 36.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.05 - 36.15 | 36.15 - 36.27 |
| Low: | 34.88 - 35.01 | 35.01 - 35.15 |
| Close: | 35.56 - 35.76 | 35.76 - 35.98 |
Wed, 24 Apr 2024
Lions' Amon-Ra St. Brown Extension Sets a Bar Justin Jefferson Will Clear - Sports Illustrated
Wed, 24 Apr 2024
AAV, friends celebrate opening of Performing Arts Center/Mud Room - Crawford county avalanche
Wed, 24 Apr 2024
Cancer risk 3 times higher in men with AAV, Turkish study finds –... - ANCA Vasculitis News
Wed, 24 Apr 2024
Duchenne muscular dystrophy gene therapy trial shows promise - European Pharmaceutical Review
Tue, 23 Apr 2024
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy ... - GlobeNewswire
Tue, 23 Apr 2024
Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Congress and ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 78 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 89 (%) |
| Shares Short | 2,970 (K) |
| Shares Short P.Month | 2,860 (K) |
| EPS | 2.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 31.82 |
| Profit Margin | 9.7 % |
| Operating Margin | 18.7 % |
| Return on Assets (ttm) | 2.1 % |
| Return on Equity (ttm) | 7 % |
| Qtrly Rev. Growth | 1.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 22.38 |
| EBITDA (p.s.) | 6.69 |
| Qtrly Earnings Growth | 3.4 % |
| Operating Cash Flow | 447 (M) |
| Levered Free Cash Flow | -148 (M) |
| PE Ratio | 15.97 |
| PEG Ratio | 2.2 |
| Price to Book value | 1.12 |
| Price to Sales | 1.59 |
| Price to Cash Flow | 6.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|